Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Dish Network’s Charlie Ergen Explores Consolidation of Telecom Businesses with EchoStar

By Anusuya Lahiri

July 7, 6:57 AM

DISH Network Corp (NASDAQ: DISH) Chair Charlie Ergen is weighing the merger

AMZN

Shiba Inu Army Cheers As Burn Rate Soars 172%, Price Rebounds

By Bibhu Pattnaik

April 20, 10:58 AM

Dogecoin killer Shiba Inu (CRYPTO: SHIB) has experienced a significant surge in its burn rate, increasing by an impressive 172%.

$SHIB

Liberty Latin America Signs Agreement With Phoenix Tower International To Monetize Mobile Tower Assets

By Benzinga Newsdesk

November 10, 9:26 AM

Transaction includes ~1,300 sites across 6 markets in the Caribbean and PanamaUnlocks significant value at an accretive cash flow multiple with $355 million of expected proceedsLiberty Latin America Ltd. ("Liberty Latin

LILA

M&A
News

Orthofix Medical Says On Dec. 2, 2022 Co. Received Follow-Up, Unsolicited Non-Binding Indication Of Interest Letter From Same Two Private Equity Fund Sponsors To Acquire All Outstanding Equity Of Co. For $24/Share In Cash

By Michael Horton

December 5, 6:36 PM

-SEC Filing

OFIX

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Dish Network’s Charlie Ergen Explores Consolidation of Telecom Businesses with EchoStar

Shiba Inu Army Cheers As Burn Rate Soars 172%, Price Rebounds

Liberty Latin America Signs Agreement With Phoenix Tower International To Monetize Mobile Tower Assets

Orthofix Medical Says On Dec. 2, 2022 Co. Received Follow-Up, Unsolicited Non-Binding Indication Of Interest Letter From Same Two Private Equity Fund Sponsors To Acquire All Outstanding Equity Of Co. For $24/Share In Cash